Machado-Joseph Deubiquitinases: From Cellular Functions to Potential Therapy Targets

Chenming Zeng, Chenxi Zhao, Fujing Ge, Yuekang Li, Ji Cao, Meidan Ying, Jin‐Jian Lu, Qiaojun He, Bo Yang, Xiaoyang Dai, Hong ZhuFrontiers in Pharmacology 2020 · DOI

Abstract

Ubiquitination is a critical post-translational modification in cancer-related pathways. Human deubiquitinases (DUBs), which modulate this process, comprise a family of approximately 100 proteins that primarily function by cleaving ubiquitin chains from substrates. The Machado-Joseph domain-containing proteases (MJDs) represent a specific DUB sub-family consisting of four members: Ataxin-3, Ataxin-3L, JOSD1, and JOSD2. While historically linked to Machado-Joseph disease, recent studies have revealed their significant roles in cancer progression. This review summarizes the cellular functions, regulatory mechanisms, and genetic alterations of MJDs across various human cancers, highlighting their potential as therapeutic targets.

Introduction

Ubiquitination serves as a molecular "code" governing protein degradation, localization, and signaling. Deubiquitinases (DUBs) act as the editors of this code. The MJD family is the smallest of the seven DUB families. Historically, research focused on Ataxin-3 due to its role in Spinocerebellar Ataxia Type 3 (SCA3), a neurodegenerative disorder caused by toxic polyglutamine (polyQ) expansions. However, the broader physiological roles of MJDs, particularly in oncology, have remained fragmented. This paper provides a unified perspective on how these four enzymes function and how their dysregulation contributes to both neurodegeneration and malignancy.

Structural and Functional Diversity

The MJD family members share a conserved catalytic core known as the Josephin domain. Despite high sequence identity between members like Ataxin-3 and Ataxin-3L (85%), their activities differ significantly. Ataxin-3’s activity is naturally restrained by specific residues, suggesting that small molecules could potentially "unlock" or further inhibit its function.

Domain structures of MJD family members, highlighting the Josephin domain and UIMs.

Furthermore, cellular localization defines their unique roles. JOSD1 is membrane-associated, regulating endocytosis and cell motility, whereas JOSD2 is primarily cytosolic, involved in general protein maintenance.

Pan-Cancer Genomic Analysis

To identify the clinical relevance of MJDs in oncology, the authors performed a pan-cancer genomic analysis using the cBioPortal database (TCGA data). This analysis mapped mutations, amplifications, and deletions across dozens of cancer types to identify which MJDs are most relevant to specific malignancies.

Pan-cancer analysis of genomic alterations (amplification, mutation, deletion) for JOSD1, JOSD2, Ataxin-3, and Ataxin-3L.

Key Findings in Cancer

  • Oncogenic Potential: JOSD1 and JOSD2 are primarily amplified in melanoma, ovarian, and uterine cancers. JOSD1 specifically stabilizes the anti-apoptotic protein MCL1 in gynecological cancers, promoting chemoresistance by preventing its degradation.
  • Context-Dependent Roles: Ataxin-3 and Ataxin-3L show higher frequencies of mutation or deletion in bladder and lung cancers. Notably, Ataxin-3 acts as a transcriptional repressor of the tumor suppressor PTEN in lung and testicular cancers; high Ataxin-3 levels correlate with low PTEN and increased tumor growth.

Role in Machado-Joseph Disease (SCA3)

In its physiological state, Ataxin-3 interacts with E3 ligases (such as CHIP and parkin) to facilitate the clearance of misfolded proteins. In SCA3, polyQ expansion leads to Ataxin-3 aggregation. This results in a "double hit" of toxic gain-of-function from aggregates and a loss of normal protein quality control. Emerging evidence also suggests that epigenetic factors, such as DNA methylation at the Ataxin-3 promoter, may influence the stability of pathogenic CAG repeats.

Conclusion and Future Perspectives

MJDs are emerging as critical regulators in both neurodegeneration and cancer. While they represent promising therapeutic targets, several challenges remain. There is currently a lack of potent, selective small-molecule inhibitors for MJDs compared to other DUB families. Additionally, the biological role of Ataxin-3L remains poorly understood. Future research must correlate MJD expression with clinical outcomes in patient samples to validate these enzymes as viable biomarkers and drug targets.

Summary updated

Abstract

Ubiquitination is known as important post-translational modification in cancer-related pathways. Human deubiquitinases (DUBs), with functions of modulating the ubiquitination process, are a family with about 100 proteins. They mainly function by cutting ubiquitin chains of the substrates. The Machado-Joseph domain-containing proteases (MJDs) is one of the sub-families of DUBs, consisting of four members, namely, Ataxin-3, Ataxin-3L, JOSD1, and JOSD2. Recent studies have provided new insights into biological functions of MJDs in the progression of Machado-Joseph disease or cancer diseases. In this review, we summarized the cellular functions and regulatory mechanisms of MJDs in Machado-Joseph disease and cancer pathways. Furthermore, we summarized MJDs genetic alterations in different human cancers by exploring the public databases (cBioportal). The aim of this review is to provide a comprehensive account based on our current knowledge about emerging insights into MJDs in physiology and disease, which might shed light on fundamental biological questions and promise to provide a potential target for therapeutic intervention.
BibTeX
@inproceedings{zeng2020machado,
  author = {Chenming Zeng and Chenxi Zhao and Fujing Ge and Yuekang Li and Ji Cao and Meidan Ying and Jin‐Jian Lu and Qiaojun He and Bo Yang and Xiaoyang Dai and Hong Zhu},
  title = {{Machado-Joseph Deubiquitinases: From Cellular Functions to Potential Therapy Targets}},
  booktitle = {Frontiers in Pharmacology},
  year = {2020},
  doi = {10.3389/fphar.2020.01311},
}
Figure